The stock of TESARO Inc (NASDAQ:TSRO) is a huge mover today! The stock increased 4.92% or $6.46 on November 23, hitting $137.73. About 814,829 shares traded hands. TESARO Inc (NASDAQ:TSRO) has risen 198.83% since April 22, 2016 and is uptrending. It has outperformed by 193.42% the S&P500.
The move comes after 8 months positive chart setup for the $7.18B company. It was reported on Nov, 24 by Barchart.com. We have $144.62 PT which if reached, will make NASDAQ:TSRO worth $359.00 million more.
Analysts await TESARO Inc (NASDAQ:TSRO) to report earnings on February, 23. They expect $-1.97 earnings per share, down 4.23% or $0.08 from last year’s $-1.89 per share. After $-1.98 actual earnings per share reported by TESARO Inc for the previous quarter, Wall Street now forecasts -0.51% EPS growth.
TESARO Inc (NASDAQ:TSRO) Ratings Coverage
Out of 13 analysts covering Tesaro Inc (NASDAQ:TSRO), 11 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 85% are positive. Tesaro Inc has been the topic of 23 analyst reports since August 24, 2015 according to StockzIntelligence Inc. FBR Capital initiated the stock with “Outperform” rating in Wednesday, April 13 report. The firm has “Buy” rating given on Friday, February 5 by Lake Street. The rating was maintained by RBC Capital Markets on Monday, October 10 with “Outperform”. The firm earned “Buy” rating on Friday, August 5 by Mizuho. The stock of TESARO Inc (NASDAQ:TSRO) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The rating was downgraded by Raymond James to “Mkt Perform” on Friday, November 4. The stock of TESARO Inc (NASDAQ:TSRO) has “Outperform” rating given on Thursday, January 21 by Wedbush. Bank of America initiated TESARO Inc (NASDAQ:TSRO) on Tuesday, August 30 with “Neutral” rating. The firm earned “Buy” rating on Thursday, March 17 by Citigroup. Wedbush maintained TESARO Inc (NASDAQ:TSRO) on Friday, August 5 with “Outperform” rating.
According to Zacks Investment Research, “Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.89 in 2016 Q2. Its up 0.34, from 1.55 in 2016Q1. The ratio improved, as 24 funds sold all TESARO Inc shares owned while 36 reduced positions. 34 funds bought stakes while 59 increased positions. They now own 44.90 million shares or 3.32% less from 46.44 million shares in 2016Q1.
Vanguard last reported 2.22M shares in the company. Creative Planning last reported 0% of its portfolio in the stock. Blackrock Invest Management Limited Liability has 115,081 shares for 0.01% of their US portfolio. Sei Invs holds 68 shares or 0% of its portfolio. Venbio Select Advisor Ltd has 9.6% invested in the company for 514,000 shares. Schwab Charles Inv Inc owns 107,043 shares or 0.01% of their US portfolio. Royal Bankshares Of Canada accumulated 8,759 shares or 0% of the stock. Teachers Retirement System Of The State Of Kentucky holds 0.02% of its portfolio in TESARO Inc (NASDAQ:TSRO) for 15,135 shares. Century Cos Inc holds 0% or 26,729 shares in its portfolio. Rhumbline Advisers holds 24,759 shares or 0.01% of its portfolio. Moreover, Perceptive Advsrs Limited Company has 6.66% invested in TESARO Inc (NASDAQ:TSRO) for 1.14 million shares. Credit Suisse Ag holds 66,035 shares or 0.01% of its portfolio. Fred Alger last reported 0.05% of its portfolio in the stock. Whittier Tru Com accumulated 0.04% or 10,839 shares. Raymond James Assoc holds 11,062 shares or 0% of its portfolio.
Insider Transactions: Since June 10, 2016, the stock had 0 insider purchases, and 6 sales for $4.43 million net activity. Hanke Jeffrey H. sold $929,321 worth of TESARO Inc (NASDAQ:TSRO) on Thursday, June 30. On Wednesday, September 21 Huber Martin H. Jr. sold $44,113 worth of the stock or 408 shares. 7,000 shares were sold by English Edward C, worth $619,803.
TSRO Company Profile
TESARO, Inc. (TESARO), incorporated on March 26, 2010, is an oncology-focused biopharmaceutical company. The Firm acquires, in-licenses and develops oncology product candidates. The Firm operates in business of developing and commercializing oncology-focused therapeutics segment. The Firm has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.